Inventiva announces positive results from Phase IIa clinical study with odiparcil in mucopolysaccharidosis type VI

Ads

You May Also Like

The Board of Directors of Orion Corporation decided on an incentive plan for key persons

                                                                         ORION CORPORATION  STOCK EXCHANGE RELEASE    2 FEB 2016  AT 14:45 PM EET               ...